| ￥3300 | |
| Z05786-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 68.87 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 90-120 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of RET, His, Human is greater than 95% as determined by SEC-HPLC. »
RET, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | RET is a proto-oncogene encoding a receptor tyrosine kinase. RET regulates key aspects of cellular proliferation, differentiation and survival. The activation of RET via gene fusions or point mutations is closely related to lung, thyroid and other cancers. |
| Synonyms | Cadherin family member 12; CDHF12; CDHR16; PTC; RET51; HSCR1; MTC1; RET-ELE1; RET51 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
